Former Bristol-Myers R&D chief signs on at VC firm

Former Bristol-Myers Squibb ($BMY) R&D chief Elliott Sigal is making the leap into venture capital. Sigal is joining New Enterprise Associates, where former MedImmune CEO David Mott has been leading the healthcare crew. Report

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.